HALO  valuation analysis

Basics
Name: Halozyme Therapeutics Inc
Description: Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Nov 02, 2021
Market cap: $5.80B (663rd)
Sales(TTM): $463.01M (1232nd)
Earnings(TTM): $409.10M (555th)

Value
FFER: 1.74 (why)
Actual price: $39.53
FFEThis is Halozyme Therapeutics Inc's the estimated price. FFEs are the denominator of the FFER ratio.: $22.66
Quantile: HALO is expensive given its fundamentals.
Prices as of EOD 2021-12-22
Price & Estimates
Sales & Earnings history (TTM)
Notable
  • Halozyme Therapeutics Inc's earnings grew by 1800.7% ($21.52M to $409.10M) over one year against a market average growth of 307.8%.
  • Halozyme Therapeutics Inc's sales grew by 132.0% ($199.56M to $463.01M) over one year against a market average growth of 16.3%.
  • Halozyme Therapeutics Inc's operating income grew by 759.1% ($34.57M to $296.99M) over one year against a market average growth of 121.0%.
Earnings / MarketCap
Halozyme Therapeutics Inc
"Biotechnology" industry
Sales / MarketCap
Halozyme Therapeutics Inc
"Biotechnology" industry
Book / MarketCap
Halozyme Therapeutics Inc
"Biotechnology" industry
Equity / Assets
Halozyme Therapeutics Inc
"Biotechnology" industry